Shailender Bhatia, MD

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Merck
    Topic: 
    Research funding
    Date added: 
    03/09/2023
    Relationship end date: 
    03/10/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    NantKwest
    Topic: 
    Research funding
    Date added: 
    03/09/2023
    Relationship end date: 
    05/31/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Nektar Therapeutics
    Topic: 
    Research funding
    Date added: 
    03/09/2023
    Relationship end date: 
    02/28/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Novartis
    Topic: 
    Research funding
    Date added: 
    03/09/2023
    Relationship end date: 
    04/30/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Trisalus Life Sciences
    Topic: 
    Research funding
    Date added: 
    03/09/2023
    Relationship end date: 
    03/10/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Xencor
    Topic: 
    Research funding
    Date added: 
    03/09/2023
    Relationship end date: 
    03/10/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Regeneron/Sanofi
    Topic: 
    Advisory board
    Date added: 
    03/09/2023
    Relationship end date: 
    06/15/2021

Pages

Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology